218 related articles for article (PubMed ID: 7996459)
1. Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.
Zhang SP; Zhou LW; Weiss B
J Pharmacol Exp Ther; 1994 Dec; 271(3):1462-70. PubMed ID: 7996459
[TBL] [Abstract][Full Text] [Related]
2. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
Zhou LW; Zhang SP; Qin ZH; Weiss B
J Pharmacol Exp Ther; 1994 Feb; 268(2):1015-23. PubMed ID: 8113958
[TBL] [Abstract][Full Text] [Related]
3. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
4. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA.
Weiss B; Zhou LW; Zhang SP; Qin ZH
Neuroscience; 1993 Aug; 55(3):607-12. PubMed ID: 8413923
[TBL] [Abstract][Full Text] [Related]
6. Intrastriatal administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor mRNA inhibits D2 dopamine receptor-mediated behavior and D2 dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine.
Zhou LW; Zhang SP; Weiss B
Neurochem Int; 1996 Dec; 29(6):583-95. PubMed ID: 9113126
[TBL] [Abstract][Full Text] [Related]
7. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
8. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
Hu XT; Brooderson RJ; White FJ
Neuroscience; 1992 Sep; 50(1):137-47. PubMed ID: 1357592
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
11. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats.
Pollack AE; Thomas LI
Pharmacol Biochem Behav; 2010 Jan; 94(3):346-51. PubMed ID: 19800912
[TBL] [Abstract][Full Text] [Related]
12. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
Qin ZH; Zhou LW; Zhang SP; Wang Y; Weiss B
Mol Pharmacol; 1995 Oct; 48(4):730-7. PubMed ID: 7476901
[TBL] [Abstract][Full Text] [Related]
13. Super-stereotypy I: enhancement of a complex movement sequence by systemic dopamine D1 agonists.
Berridge KC; Aldridge JW
Synapse; 2000 Sep; 37(3):194-204. PubMed ID: 10881041
[TBL] [Abstract][Full Text] [Related]
14. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
Boldry RC; Chase TN; Engber TM
J Pharmacol Exp Ther; 1993 Dec; 267(3):1454-9. PubMed ID: 7903390
[TBL] [Abstract][Full Text] [Related]
15. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Wirtshafter D; Osborn CV
Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
[TBL] [Abstract][Full Text] [Related]
16. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
Schmidt HD; Pierce RC
Neuroscience; 2006 Oct; 142(2):451-61. PubMed ID: 16844308
[TBL] [Abstract][Full Text] [Related]
17. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
18. Anatomical localization of SKF-38393-induced behaviors in rats using the irreversible monoamine receptor antagonist EEDQ.
Neisewander JL; Ong A; McGonigle P
Synapse; 1995 Feb; 19(2):134-43. PubMed ID: 7725242
[TBL] [Abstract][Full Text] [Related]
19. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
20. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.
DeBoer P; Abercrombie ED
J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
